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ABSTRACT
Pharmacoepidemiology is used extensively in osteoporosis research and involves the study of the use and effects of drugs in large
numbers of people. Randomized controlled trials are considered the gold standard in assessing treatment efficacy and safety.
However, their results can have limited external validity when applied to day-to-day patients. Pharmacoepidemiological studies aim
to assess the effect/s of treatments in actual practice conditions, but they are limited by the quality, completeness, and inherent bias
due to confounding. Sources of information include prospectively collected (primary) as well as readily available routinely collected
(secondary) (eg, electronic medical records, administrative/claims databases) data. Although the former enable the collection of ad
hocmeasurements, the latter provide a unique opportunity for the study of large representative populations and for the assessment
of rare events at relatively low cost. Observational cohort and case-control studies, the most commonly implemented study designs
in pharmacoepidemiology, each have their strengths and limitations. However, the choice of the study design depends on the
research question that needs to be answered. Despite themany advantages of observational studies, they also have limitations. First,
missing data is a common issue in routine data, frequently dealt with usingmultiple imputation. Second, confounding by indication
arises because of the lack of randomization; multivariable regression and more specific techniques such as propensity scores
(adjustment, matching, stratification, trimming, or weighting) are used tominimize such biases. In addition, immortal time bias (time
period during which a subject is artefactually event-free by study design) and time-varying confounding (patient characteristics
changing over time) are other types of biases usually accounted for using time-dependentmodeling. Finally, residual “uncontrolled”
confounding is difficult to assess, and hence to account for it, sensitivity analyses and specific methods (eg, instrumental variables)
should be considered. © 2018 The Authors. JBMR Plus is published by Wiley Periodicals, Inc. on behalf of the American Society for
Bone and Mineral Research.
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Introduction
The field of pharmacoepidemiology (PE) was developed toenable the study of drug adverse events in the wider
populations and to emphasize the importance of well-designed
research to characterize the utilization and effects of drugswhen
used in actual practice and in the community.(1) PE applies
epidemiologic methods to clinical pharmacology to provide an
estimate of the probability of beneficial or adverse effects of a
treatment in populations.(2) Health care professionals, policy
makers, and patients usually seek the highest level of
information about the effects of treatments. Nevertheless, it is
estimated that more than half of medical treatments lack valid
evidence of effectiveness, particularly for long-term and patient-
centered outcomes.(3,4)
Similar to other clinical research, the selection of the study
design for PE studies depends on the research question.
Randomized controlled trials (RCTs) are considered the gold
standard for providing the highest level of evidence about the
efficacy and safety of treatments. In osteoporosis research,
numerous high-quality RCTs have been conducted to assess the
efficacy (under ideal and controlled circumstances) and safety
(in restricted populations) of anti-osteoporosis medications.(5–9)
Despite the strengths of those studies, they have their
limitations and their results do not reflect the true effects of
anti-osteoporosis treatments in real-world patients and actual
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practice settings. On the other hand, observational studies,
using large data sets to study the effectiveness (under real-world
conditions) of these same medications (once marketed), have
been conducted extensively in osteoporosis research, and their
findings complement those from RCTs.(10–13) With longer follow-
up, the inclusion of more complex and older patients, and larger
patient numbers, observational studies can, under certain
assumptions and when properly conducted and analyzed,
identify clinically important effects and study rare outcomes
better than RCTs.(14) Hence, the use of such studies for post-
marketing surveillance as recommended by drug regulatory
agencies.(15) Nevertheless, observational studies have a lot of
challenges, including bias and issues with completeness and
validity resulting from the nature of these data, and the
conditions under which they are collected. Careful framing of
the research question with appropriate study design and
application of statistical analysis techniques can yield findings
with validity and improve our understanding of treatment
effects.(16)
This review discusses (with a focus on anti-osteoporosis
treatments) the differences between RCTs and observational
studies in the study of drug effects. It summarizes the types of
data sources used and the common study designs implemented
in pharmacoepidemiology and explores the opportunities of
such data, including the breadth of information sources and
their inherent challenges and how to deal with them.
Randomized Controlled Trials and
Observational Studies
RCTs are the main method for evaluating the efficacy and safety
of treatments. They are conducted under highly controlled
conditions to ensure high internal validity and compliance, thus
ensuring that differences in outcomes can solely be attributed to
differences between the drug and placebo.(17) Although RCTs
have a lot of advantages, their design limits their ability to
provide answers about issues commonly encountered by
clinicians in real-world patient settings (Table 1). It has been
reported that 50%(18) to 80% of patients receiving treatment for
osteoporosis would not be eligible for a randomized controlled
trial because of comorbidities, previous treatment with bone-
active agents, or the use of other medications.(19) Therefore,
results from RCTs may have limited generalizability to the
general patient population. Furthermore, because RCTs have a
limited duration of follow-up time (commonly 3 years) with a
restricted sample size, their ability to identify rare or long-term
adverse events associated with the use of osteoporosis
medication is limited.(15) For example, bisphosphonates (BP),
first-line anti-osteoporosis medications, have been linked to rare
but severe adverse events, including osteonecrosis of the jaw
(ONJ) and subtrochanteric atypical femoral fractures (AFF).
Those events could not be captured in the clinical trials or the
extension trials, which tested the long-term efficacy and safety
of BPs (the FLEX study and HORIZON extension study) because
those trials were not initially designed to investigate ONJ and
AFF and the low incidence of those adverse events meant their
statistical power was insufficient.(20) Most of the evidence about
ONJ and AFF was reported in observational studies utilizing
large health care databases that had longer follow-up and
included larger numbers of people.(21,22)
Pharmaceutical manufacturers conduct RCTs (premarketing
clinical trials) to investigate the therapeutic benefits and safety
of new treatments before they get approved for marketing and
prescribing by practitioners. Drawing on results from RCTs and
the use of those drugs by the general population, postmarketing
studies, which are observational in nature, are developed and
have become essential to further study the effects of those new
drugs in larger populations.(23) Hence, observational studies can
be used to complement findings from RCTs because they can
use large sample-sized patient populations that include
clinically important subpopulations (eg, elderly, complex
patients, and those exposed to polypharmacy), many of which
might be excluded from randomized controlled trials(15)
(Table 1). For example, patients with severe chronic kidney
disease (CKD) were excluded from most RCTs conducted for
studying the effects of bisphosphonates. Therefore, the
potential risks and benefits of those medications in this growing
group of the population are unknown, and hence first-line
therapies (eg, bisphosphonates) are contraindicated in this
relevant at-risk population. Additionally, compliance issues
usually observed in the community(24) are unlikely to be present
in RCTs, hence limiting the transportability of treatment effects
from one setting to another.
Although RCTs provide the highest level of evidence, a few
meta-analyses comparing treatment results from RCTs and
well-designed observational studies across a range of clinical
conditions have found that although discrepancies can occur,
the estimates of treatment effects are similar.(25–27) A retrospec-
tive cohort study comparing the real-world effectiveness of
osteoporosis medications risedronate to alendronate and
calcitonin using an administrative claims database confirmed
the fracture risk reduction at 6 and 12 months of risedronate
and alendronate that was shown in RCT data and pooled post
hoc analyses of the same treatments.(10) The similarity of the
results of the two differently designed studies suggests that
observational studies can confirm and extend the results
obtained from RCTs to a broader population.
Observational studies, as stated earlier, can be conducted in
subpopulations that are usually excluded or underrepresented
in RCTs. Hence, the results from those studies can validate the
use of treatments in certain groups (Table 1). For example,
high-quality evidence supports the use of alendronate for
prevention of vertebral fractures among glucocorticoid-treated
patients, but the quality of evidence is low for prevention of
nonvertebral fractures; evidence is lacking for prevention of hip
fracture because the RCTs were small and were not designed to
Table 1. The Difference Between Randomized Controlled Trials
and Observational Studies
Randomized controlled trials Observational studies
Proves causal inference—
highest level of evidence
Complements findings from




other types of biases
Non-randomized and
susceptible to biases
High cost and short duration Low cost and long follow-up
Limited potential for study of
rare and long-term adverse
events
Suitable for study of rare
adverse events and long-
term outcomes
Small sample and strict
inclusion criteria
Large sample and diverse
patients
Limited generalizability Reflects real-world settings
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study rare events such as hip fractures.(28,29) To close this
evidence gap, a recent retrospective cohort study using a
Swedish national database of 433,195 patients aged 65 or older
investigated whether alendronate treatment in older patients
using prednisolone (the primary glucocorticoid for long-term
treatment of inflammatory diseases) was associated with
decreased hip fracture risk. The results showed that among
older patients using medium to high doses of prednisolone,
alendronate treatment was associated with a significantly lower
risk of hip fracture over a median of 1.32 years.(30)
Sources of Data for Pharmacoepidemiological
Studies
The research question usually defines the type of data required
for a certain study. Data sources are broadly classified into
primary (actively collected) and secondary (routinely collected
or existing) data sources.(31) Important considerations for
choosing data include whether the key variables are available
to identify exposures, outcomes, and confounders. Data should
be highly detailed, contain historical information to determine
baseline patient characteristics, and represent an adequate
duration of follow-up.(31)
Primary data sources
Primary data involve the collection of new data by the
investigator directly from study participants with prospective
follow-up from a certain time point to the future/outcome of
interest. They can be tailored to answer the exact research
question by collecting specific exposure variables and therefore
be more complete. However, prospective data collection has
several drawbacks, including being time-consuming, loss to
follow-up, hawthorne effect (change in behavior while being
“observed”), and high cost.(32)
Prospective observational studies
These studies collect data from subjects and subsequently
observe them over time for the effects of specific treatments on
particular outcomes. A classic example of prospective cohort
studies is the Framingham Heart Study (FHS), one of the first
longitudinally followed large cohort studies initiated in 1948,
which also has an ancillary study, the Framingham Osteoporosis
Study.(33) Another example is the Dubbo Osteoporosis Epidemi-
ology Study (DOES), one of the longest-running prospective
observational cohort studies of osteoporosis in women andmen
internationally.(34)
Registries
Registries are also primary data sources that are systematically
collected for research. Patients are typically identified when
they present for care, and the data collected generally include
clinical and laboratory tests and other information such as
the length of their hospital stay and their socioeconomic
status. Registries are defined by specific diseases/conditions,
exposures (eg, to drug products), time periods, or popula-
tions.(31) The Global Longitudinal Study of Osteoporosis in
Women (GLOW) is a prospective registry study that involved
forming an osteoporosis registry for women aged 55 years
and older by collecting data from 10 countries over a five-year
period.(35)
Secondary data sources: routinely collected health data
The growing trend of the development of large-scale routinely
collected health data in the past 20 years has resulted in an
increase in the use of large patient information sources in
pharmacoepidemiology.(36) The two main types of databases
available for observational studies are electronic medical
records (produced as a result of clinical care) and administrative
databases (by-product of financial transactions).(37) These data-
bases have a lot of advantages, including their large size that
allows the study of rare events, their representativeness, and
their availability at relatively low cost and without long delays,
which makes them accessible and efficient.(36) Studies con-
ducted using secondary data sources are usually conducted
using readily available data, collected in the past. Because
investigators do not have control over the process of data
collection as in prospective studies, key variables required for
the study might be unavailable in an otherwise ideal data set.
Hence, linking different data sets or using already linked ones
provides richness to the study information.(31)
A number of primary care records databases are available
worldwide. Commonly used ones in the bone research field
are the UK Clinical Practice Research Datalink (CPRD) and the
Catalan Sistema d’Informacio pel Desenvolupament de
l’Investigacio en Atencio Primaria (SIDIAP). Their data have
been linked to many other data sets to address questions about
the risks and benefits of different treatments. In a recent
example, the CPRD data set and SIDIAP have been linked to
inpatient data, national renal registries, and mortality data to
study the association between the use of oral bisphosphonates
and a number of outcomes in patients with moderate-severe
chronic kidney disease (CKD). The findings from the UK data
have been presented recently in the form of conference
abstracts(38–40) and are now being replicated in the Catalan
data set for confirmation.
In other regions like Denmark and Sweden, excellent quality
secondary care data are available. Given the existence of a
unique person identifier throughout the health and social
systems, patient data can be obtained from hospital (out- and
inpatient) records, linked to pharmacy dispensations data, and
sociodemographic information. Numerous pharmacoepidemio-
logical studies have been conducted in the field of osteoporosis
using such data, including a recent example where more than
60,000 users of alendronic acid were observed for up to 10 years
to study the effects of long-term bisphosphonate users on rare
outcomes such as osteonecrosis of the jaw and femoral shaft
fractures.(21,22)
Common Designs of Pharmacoepidemiological
Studies
The goal of observational pharmacoepidemiological studies is to
identify the association between different exposures or treat-
ments and specific outcomes. Different study designs are used in
pharmacoepidemiologic research (Table 2).(41) Descriptive
studies describe the distribution of disease or other health
outcomes in populations, whereas analytical studies test
hypotheses by studying the association between different
factors and outcomes. However, two of the most commonly
implemented study designs are cohort and case-control studies,
which offer the advantage of measuring the association
between certain treatments and health outcomes with a
temporal dimension.(32)
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Cohort studies
In cohort studies, participants are identified based on their drug
exposure and followed over time for the rates of outcomes
(incidence, relative risks). Cohort studies can be prospective or
retrospective. Prospective cohort studies involve following up
participants from the present time to the future. They are
designed to actively collect data from participants and hence
specific variables required to answer the research question can
be obtained. However, they can be expensive to conduct,
require long duration of follow-up, especially for rare outcomes,
and they are susceptible to loss to follow-up.(42) Retrospective
cohort studies involve identifying participants based on their
drug exposure and then looking into their past to examine
certain outcomes. Themain disadvantage of this study design is
the limited control the investigator has over data collection.(43)
Table 3 lists the advantages and disadvantages of cohort
studies.
Case-control studies
In case-control studies, participants are identified based on their
outcomes, cases are those who have the outcomewhile controls
do not, and the past exposure to drug is compared between the
two groups. They use retrospectively collected data and are best
used to study rare outcomes and those with long latency period.
In comparison to cohort studies, case-control studies cannot
estimate risks, are quick, less expensive to conduct, require a
smaller sample, and can assess multiple drug exposures for one
outcome.(43,44) Table 3 lists the advantages and disadvantages of
case-control studies.
Atypical Femoral Fractures and Bisphosphonate
Use in Pharmacoepidemiology
Long-term bisphosphonate use has been linked to the
occurrence of atypical femoral fractures (AFFs). AFF is a rare
adverse event characterized by a noncomminuted, transverse
fracture of the subtrochanteric or femoral shaft regions with
specific radiological features.(45) Studying AFFs is a good
example to explore the different types of study designs and
data sources that could be used in pharmacoepidemiology and
how different analyses could yield mixed results. AFFs were first
described in case series in 2005.(46) This was followed bymultiple
case reports and case series,(47–49) secondary analyses of results
from randomized controlled trials and extension trials,(50) cross-
sectional studies,(51) prospective(52) and retrospective cohort
studies,(53,54) case-control studies,(55,56) and hybrid studies.(22,57)
Studies of AFFs and their association with bisphosphonates
fall into two general categories. First are fractures identified
using large registry or database approaches with International
Classification of Diseases, 9th edition (ICD-9), but no radio-
graphic adjudication to confirm features of atypia.(58) Most of
those studies showed that atypical fracture rates have increased
in patients exposed to bisphosphonates. However, typical and
atypical fractures were not distinguished in these studies
because original radiographs were not reviewed and hence
AFFs rates were overestimated.(59) Second are fractures
ascertained by radiographs. Those studies showed that the
absolute incidence of AFFs is relatively low, but there is a
significant association between bisphosphonates and AFFs.(60)
Opportunities for Pharmacoepidemiological
Studies
As stated previously, conducting observational (cohort, case-
control, and others) studies has many advantages. Using large
health care databases may include a wide variety of data
because various forms of health care information can be linked.
They include very large numbers of diverse patients (including
those not typically recruited in RCTs because of comorbidity,
sociodemographics, or logistics), registered in potentially any
treatment center/s (including nonspecialized ones), with long
follow-up and at much lower cost.(14) This enables the study of
rare events and allows for generalizability of the results.(61)
Furthermore, some databases contain detailed information
about drug use, including initiation and discontinuation data,
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Table 3. Advantages and Disadvantages of Cohort and Case-Control Studies
Type of study Advantages Disadvantages
Cohort Better in finding a causal link Not suitable for rare diseases or diseases with long
latency as large number of subjects required
Suitable for rare exposures and examining multiple outcomes
for one exposure
Problems with loss to follow-up
Prospective design (usually) Requires long duration and is more expensive
Estimation of absolute and relative risks Susceptible to confounding by indication and
immortal time bias
Case-control Suitable for rare outcomes or outcomes with long latency Not suitable for rare exposures
Quicker to conduct and lower costs than cohort studies Difficult to find an appropriate control group
No problem with loss to follow-up Cannot estimate risks
Requires smaller sample size Susceptible to recall and interviewer bias
190 ALARKAWI ET AL. JBMR Plus (WOA)
reason/s for discontinuation, number of prescriptions, and
dosing regimens. This allows for assessing treatment persistence
and compliance and its effect on clinical outcomes in typical
patient settings.(16) In a recent example, a review of observa-
tional prospective and retrospective studies investigating the
adherence, compliance, and persistence with osteoporosis
therapies in North America and Europe indicated that low
compliance and persistence rates for osteoporosis therapies in
the real-life setting results in increased rates of fragility
fractures.(62)
Challenges of Pharmacoepidemiological Studies
Although observational studies have numerous benefits and
their findings can confirm and complement findings from RCTs,
they also have a number of limitations which may prove
challenging. As previously mentioned, a limitation of prospec-
tive cohort studies specifically is the long follow-up period while
waiting for events or diseases to occur. This design is inefficient
for investigating diseases with long latency periods and is
vulnerable to a high loss-to-follow-up rate. In addition, those
studies are expensive to conduct.(32) Although retrospective
studies using health care databases may be more practical, the
information has not been collected specifically for research
purposes and there are concerns about the accuracy and
precision of the data used in those studies. For example, errors in
data coding can result in misclassification of drug exposure and
outcomes as well as diagnostic misclassification.(16,36,61) In
addition, the data are limited to available variables in the data
source. Therefore, there may be issues with missing data
elements and unmeasured confounders. Ensuring high-quality
data and integrity is vital for research studies; however, data
quality and details of information differ substantially among
health care databases worldwide.(16,36,61) Fortunately, examples
exist of databases where fractures have been validated with
good accuracy, including both primary care (CPRD(63) and
SIDIAP,(64,65) amongst others) and secondary care (eg, Danish
registries(66)) data.
In addition to the challenges outlined above, observational
studies are associated with methodological issues, including
different types of biases that can affect the internal and external
validity of the study if they have not been adequately accounted
for. These methodological issues are not as obvious as the ones
previously described and may be the most challenging. The
following section discusses some of the most important
challenges that face researchers when conducting observational
studies and techniques to address them, includingmissing data;
selection bias, which is more commonly known in pharmacoe-
pidemiology studies as confounding by indication; immortal time
bias and time-varying confounding, which are associated with
changes in drug exposure and covariates during the follow-up
period; and uncontrolled confounding, also known as residual
confounding, which is related to unmeasured confounders.
Missing data
Using databases with large amounts of missing information that
do not have rigorous and standardized data editing, cleaning,
and processing procedures increases the risk of inconclusive and
potentially invalid study results.(31) Missing data is a frequent
complication of any real-world study. The causes of missingness
are often numerous, some due to design and some to chance.
Some variables may not be collected from all subjects,
some subjects may decline to provide values, and some
information may be purposely excised, for example to protect
confidentiality.(67)
There are a few methods to deal with missing data. It is
important to recognize which variables are missing and the
pattern of their missingness. For the initial analysis, an analysis of
non-missing values can be performed, called a complete-case
analysis.(68) However, this approach can reduce the sample
size and hence the power of the study, as well as incur selection
bias, as patients with measures available will (in actual practice)
tend to be different from those without.
Multiple imputation is a general approach to the problem of
missing data. It involves complex statistical modeling aimed to
allow for the uncertainty about the missing data by creating
several different plausible imputed data sets and appropriately
combining results obtained from each of them. Multiple
imputation analyses will avoid bias when missing is “at random”
(ie, completely at random conditional on certain characteristics
such as age or comorbidity) and when enough predictors of
missingness and of missing values, as well as the outcome
variable are included in the imputation model.(67)
Confounding by indication bias
Clinicians usually prescribe medications based on multiple
factors, including the severity of patients’ illness and their
clinical, behavioral, and functional characteristics. If some of
these factors are imbalanced between drug users and non-users
and independently associated with the study outcome, then
failing to control for such variables can lead to confounding by
indication bias.(36) Confounding by indication can sometimes be
minimized by design (eg, in case-only studies) or controlled for
at the analytical stage using statistical methods, including
restriction,multivariable adjustment, stratification, weighting, or
matching.(69,70)
Propensity score (PS) analyses have become one of the most
popular methods to control for confounding by indication. It is
defined as the conditional probability of being treated given the
patients’ characteristics. PS can thus be used to balance
between-group differences and hence reduce bias.(71) When a
PS is calculated, it can be used in adjustment, matching,
stratification, or in inverse probability weighting. Matching on
the propensity score takes several approaches, but all are
centered on finding the nearest match of a treated individual to
a comparison subject(s) based on the scalar propensity score.(72)
In a recent prospective study that examined the effect of
osteoporosis medication on mortality risk using the DOES
cohort, a propensity scorematched set was created bymatching
each treated participant with a non-treated participant with a
similar propensity score or similar likelihood of being treated.(11)
Immortal time bias and time-varying confounding
Immortal time bias (ITB) is a common issue in pharmacoepi-
demiology. ITB occurs when the event of interest/outcome
could not have occurred for a certain time span because of the
chosen study design and/or data analysis methods.(73) For
example, if a subject is observed from the time he had a hip
fracture (index date) but the exposure started at the date of a
first prescription of oral bisphosphonate after the fracture, the
period of time from the index date to the first prescription date is
“immortal” for drug users, as the patient must be alive to
become a user. This bias systematically overestimates the
outcome rate in the untreated group, while underestimating the
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rate in the treated group, therefore creating the illusion that the
drug (here, oral bisphosphonate) is preventive against the
outcome of interest. To avoid this bias, all immortal time should
be fully accounted for in the analysis. A potential solution at the
design stage is the use of a time-varying exposure, where drug
users are considered as non-users for the time that begins from
index (hip fracture) to start (first prescription) date. After
treatment initiation/exposure to drug, subjects are then
classified as exposed/treated.(73)
In addition to time variations in treatment initiation, other
covariates that affect treatment exposure and outcome may
also vary throughout follow-up, resulting in the so-called
time-varying confounding. This type of confounding can
partially be controlled for using the time-dependent analyses,
where patient characteristics for drug users should be
considered at the index date for the “non-user” time and
then reevaluated before start date for the user time.(74) Other
advanced methods can be used to more accurately account
for time-varying confounding, including inverse probability
treatment weighting(75) and marginal structural equations,
amongst others.(76)
Residual confounding and unmeasured confounders
In some studies, incompletely controlled “residual” confound-
ing can occur for several reasons. Some confounders for the
exposure or outcome may not be identified or measured in
routine practice.(77) For example, bone mineral density (BMD)
has been reported to be an independent determinant of
fracture risk and all-cause mortality.(78,79) However, observa-
tional studies using secondary data sources such as adminis-
trative databases or primary care medical records do not
usually have BMD results. Hence, the inability to adjust for BMD
as a confounder can provide inaccurate effect estimates.
Furthermore, residual confounding might still persist after
adjusting for the measured variables because of misclassifica-
tion or measurement errors.(77,80) Residual confounding can
threaten the validity of a study; therefore, it should be assessed
and approaches to estimating its effect, including sensitivity
analyses and instrumental variable (IV) approach, should be
implemented.
The purpose of these sensitivity analyses is to make informed
assumptions about the residual confounding and quantify its
effect on the relative risk estimate of the drug-outcome
association. This is performed by varying the confounder
prevalence in the exposed versus the unexposed and the
magnitude of the confounder–disease association and obtain-
ing different risk estimates over a wide range of parameter
groupings.(77,81)
Instrumental variable analyses rely on the existence of an
“instrument,” a variable that has three key characteristics: 1) it
is highly correlated with treatment; 2) it does not directly
affect the outcome (other than through the effect of the
treatment); and 3) it is not associated with potential (measured
or unmeasured) confounders.(31) One of the most common
instruments in pharmacoepidemiology is the so-called physi-
cian prescription preference, which is derived from the
assumption that different providers or physicians have
different preferences or treatment algorithms dictating how
medications should be used.(82) An example could be the
choice of anti-osteoporosis medication: the possibility that
physicians strongly differ in their preference for different anti-
osteoporosis medications suggests that an IV defined at the
level of the prescribing physician could be used to compare
treatment effects. When the three assumptions above are
fulfilled, IV analyses can account for confounding related to
both measured and unmeasured variables.
Conclusion
Pharmacoepidemiology is used extensively in osteoporosis
research and involves the study of the use and effects of drugs in
large numbers of people. Results from these studies can confirm
and complement findings from RCTs and are more generaliz-
able. Primary sources of data consist of prospective collection of
new data and registries. Secondary data sources includemedical
records and administrative databases. These have a number of
advantages, including large size, representativeness, the ability
to study rare adverse events, and to measure and account for
persistence and compliance in actual practice settings, at a
much lower cost when compared with RCTs or primary data
collection. Observational cohort and case-control studies are the
two most commonly implemented study designs in pharma-
coepidemiology. Cohort studies can be prospective (tailored to
answer the research question) and retrospective (already
collected data), each of which has its strengths and limitations.
Case-control studies are suitable for studying rare outcomes and
are cheaper to conduct. However, they are susceptible to recall
bias and finding an appropriate control group could be
challenging. Although conducting observational studies in
pharmacoepidemiology has a lot of advantages, there are also
a number of challenges. Missing data is a common complication
of using databases, which is frequently dealt with usingmultiple
imputation method. Confounding by indication arises when the
decision to treat is driven by specific risk factors present more
commonly in the treated group. Multivariable regression
modeling and propensity score analyses amongst others can
be used to minimize confounding. Immortal time bias and time-
varying confounding are other common sources of bias, which
can be accounted for using time-dependent analysis. Finally,
residual confounding due to lack of information on key variables
or measurement errors should be assessed, and sensitivity
analyses and specific methods (eg, instrumental variables)
should be considered. An understanding of these biases and
how to best overcome them is essential to both carrying out and
appraising these studies.
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